Breast Cancer
Data on Breast Cancer Published by V.G. Vogel and Colleagues
Published in Medical Letter on the CDC and FDA, June 26th, 2011
2011 JUN 26 -- New research, "Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer," is the subject of a report. According to recent research published in the journal Cancer Prevention Research, "The selective estrogen-receptor modulator (SERM) tamoxifen became the first United States. Food and Drug Administration (FDA)-approved agent for reducing breast cancer risk but did not gain wide acceptance for prevention, largely because it increased endometrial cancer and thromboembolic events."
"The FDA approved the SERM raloxifene for breast cancer risk reduction...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Vaccines
Data on Vaccines Described by T.V. Axelsen et al - Vaccines
Data on Vaccines Discussed by Researchers at Sanofi Pasteur - West Nile Virus
Findings from University of Texas Medical Branch in West Nile Virus Reported - Breast Cancer
Hotze Health & Wellness Center Warns of Oral Contraceptives Dangers beyond FDA's Safety Announcement - Influenza A Virus
Investigators at University of California Zero in on Influenza A Virus - HIV/AIDS
New Findings from Albert Einstein College of Medicine in the Area of HIV/AIDS Published - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
